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Abstract
The physiological role of autophagy in metabolism of the body involves both protein
synthesis  and degradation.  The autophagy-lysosome and the ubiquitin-proteasome
systems  are  the  two  major  intracellular  proteolytic  mechanisms.  Autophagy  in
hepatocytes is known to be quite active and contribute to its normal functions and the
pathogenesis of liver diseases. The role of autophagy in liver diseases has been widely
studied,  and growing evidence has now shown that  autophagy is  involved in the
pathogenesis of cirrhosis and hepatocellular carcinoma (HCC). However, the role of
autophagy in the progression of liver fibrosis and prognosis of human HCC is not well
known.  Recent  studies  have  demonstrated  that  tissue  factor  (TF)  combined  with
coagulation factor VII (FVII) has a pathological role by activating a protease-activated
receptor 2 (PAR2) for tumor growth. Autophagy-related LC3A/B-II formation induced
by the inhibition of TF/FVII/PAR2 coagulation axis, particularly by FVII knockdown,
was selectively mediated by the Atg7 induction. These results are consistent with clinical
observations that indicate the important role of FVII activation in regulating autophagy
in HCC. In this chapter, we discuss our findings in which FVII promotes growth and
progression in HCC through ERK-TSC/mTOR signaling to repress autophagy and may
play a pivotal role in conferring cirrhosis and other liver diseases.
Keywords: autophagy, coagulation, hepatocellular carcinoma, cirrhosis, tissue factor,
factor VII, protease-activated receptor 2, mammalian target of rapamycin
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1. Introduction
Autophagy comprises some of the most fundamental reactions in which the cell sequesters
part of its own material for degradation and converts proteins and lipids into life-preserving
fuel through times of energy deprivation. In addition, the cell also uses autophagy to remove
misfolded protein aggregates and dysfunctional organelles under certain stress conditions
[1, 2]. During autophagy, multiple signaling pathways converge on the autophagy-related
(Atg) proteins,  mediating the formation of a double-membraned structure known as the
autophagosome.  Recruitment  of  the  Atg12-Atg5  complex  and  microtubule-associated
protein 1 light chain 3 (LC3) is essential for this process and correlates with the level of
autophagy. These autophagosomes then fuse with lysosomes to form autolysosomes that
lead to the degradation and recycling of their content [3]. Despite the general acceptance
that autophagy is a protective mechanism toward cell survival, recent studies have shown
an active role of autophagy in cell death [1]. Autophagic cell death is known as the type II
programmed cell death in response to several anti-tumor therapies in various types of cancer
[3].  Recent  studies  have  revealed the  involvement  of  autophagy in  major  fields  of  liver
physiology and pathology,  including acute/chronic  liver  injury,  lipid accumulation,  viral
infection, and hepatocellular carcinoma (HCC) [4]. The autophagy pathway may be used by
liver cells to generate energy during periods of starvation or exploited as a tumor suppressor
mechanism depending on different biological contexts [5]. Studies assessing autophagy in
HCC have demonstrated an anti-tumor role in various cellular, animal and clinical models.
However,  the mechanisms underlying low incidence of autophagy in HCC are not fully
elucidated.
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that controls cell
growth and survival and is regulated by various stimuli [6]. The mTOR pathway is abnormally
activated in a proportion of HCC patients. As the name implies, mTOR is the intracellular
target of rapamycin, a naturally occurring small molecule inhibitor that is currently used
clinically as an immunosuppressant and in some cases, to inhibit tumor growth and metasta-
sis [7, 8]. In HCC animal models, inhibition of the mTOR/ribosomal protein p70 S6 kinase
(p70S6K) pathway demonstrates anti-proliferative and anti-angiogenic effects [9, 10]. Studies
using histone deacetylase (HDAC) inhibitors OSU-HDAC42 and SAHA to induce autophagy
in HCC cells further reveal that their anti-cancer properties are mainly through blockade of
Akt/mTOR signaling [11].
Our recent publications tied together autophagy and the coagulation cascade in HCC and
highlighted the important role of factor VII (FVII)/protease-activated receptor 2 (PAR2) sig-
naling in regulation of autophagy, which is dependent upon mTOR activity. More impor-
tantly, an inverse correlation between FVII/PAR2 and LC3 expression in HCC tissues and
their contiguous normal regions suggests that components of this particular pathway may
serve as potential therapeutic targets in HCC and other cancers which exhibit aberrant FVII/
PAR2/LC3 signaling.
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2. mTOR interconnects coagulation cascade and autophagy in HCC and
related disorders
An established relation between cancer and thrombosis can be dated back to more than a
century ago, and the association was further refined and supported among patients who
showed venous thromboembolism (VTE) and were subsequently diagnosed with clinically
overt cancer [12, 13]. Thrombosis is considered as one of the common complications related to
the cancer itself as well as interventions for treating the disease. Approximately 15–20% of VTE
events are associated with malignancy [14, 15]. In addition, patients with cancer have a fourfold
higher risk for VTE compared with non-cancer patients. This risk is even higher in patients
who undergo chemotherapy [16]. Recurrent VTE is also twice as likely to occur in cancer
patients, even in those who experience oral anti-coagulant therapy [17, 18]. Notably, patients
with cancer who have a thrombotic event have reduced survival compared with those who do
not [19].
The transmembrane tissue factor (TF) initiates blood coagulation cascade that complexes with
activated FVII and transmits signals through direct activation of protease-activated receptors
(PARs) [20–22]. In fact, dysregulated cancer cells may have an important contribution to the
elevated levels of circulating TF, which in turn activates the coagulation system [23]. Cancer
cells release plasma membrane vesicles with pro-coagulant activity. Such activity has been
shown to behave as TF, requiring FVII for activation [24]. The role of direct TF signaling in
cancer is not fully understood. The best known pathway of TF-dependent signaling is through
the activation of PAR2 [25, 26] and in part through the thrombin-PAR1 pathway [27, 28]. It has
also been reported a constitutive association of TF with β1 integrins in cancer [25]. Inhibition
using specific antibodies or peptide inhibitors concludes that blockade of the FVII/TF/PAR2
signaling independent of the coagulation response can suppress cancer progression [25, 29].
TF expression varies among different types of malignancies; some may be more pro-thrombotic
than others. TF levels can also be influenced by tumor staging as well as associated therapeutic
interventions [30, 31].
Plasma TF levels are closely related to occurrence of chronic liver diseases [32, 33]. The diag-
nostic/prognostic value of TF in tumor pathology has also been demonstrated [34]. Angio-
genesis is recognized as an important factor in the development, progression, and
recurrence of HCC, and targeting vascularization has been vigorously studied for potential
therapeutic strategies [35–37]. A recent study to evaluate the correlation between TF expres-
sion with tumor angiogenesis and invasiveness in HCC suggests that tissue TF levels have a
significant association with microvascular density, venous invasion, microsatellite nodules,
tumor staging, and survival [38]. Zhou et al. also demonstrates that TF is overexpressed in
both plasma and liver tissue of HCC patients, and it is closely related to many invasive and
metastasis indexes [39]. Furthermore, hepatocytes occupy more than half of the total liver
volume and carry out critical functions in coagulation factor synthesis (TF, FVII, etc.) in the
liver. It has also been discussed that extremely low levels of hepatocyte TF compared with
other organs/tissues [40, 41], however, may be the potential source for the activation of coag-
ulation in liver diseases [42].
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TF is an essential cofactor of FVII, which accelerates the conversion of an inactive FVII into an
active FVIIa, propagating a series of serine protease activation events. In addition to pathogenic
mechanisms in which TF triggers a pro-coagulant state and aberrant signaling, when TF-
expressing tumor cells are in contact with the blood or when TF-positive membrane particles
are shed into the circulation, constitutive expression of FVII also participates in the process of
tumor invasion and metastasis [43]. Studies that target the TF/FVIIa signaling pathway with
specific inhibitor or RNA interference provide a logical path for the development of potential
therapeutics [44, 45]. In our clinical observations in HCC, we were the first to demonstrate that
the expressions of FVII and PAR2 were inversely correlated with the amount of autophagic
effector proteins LC3A/B-II [46]. We have also demonstrated that the treatment with recombi-
nant TF (rTF), rFVII, or PAR2 agonist decreased expression of LC3A/B-II protein in cultured
Hep3B cells suggesting a crucial impact of the TF/FVII/PAR2 coagulation pathway on tumor
malignancy under certain circumstances. The dependence of mTOR activation on pathological
thrombosis has been seen in various studies, in which the risk of thrombotic events while
patients were receiving organ transplants [47–52] and coronary stents [53] was associated with
TF expression. In this study, treatment with rTF, rFVII, and the PAR2 peptide agonist, rather
than thrombin and PAR1 agonist, induced activation and expression of mTOR whereas
silencing of TF, FVII, or PAR2 by siRNAs repressed its phosphorylation and expression.
Additionally, rTF, rFVII, or PAR2 activation drastically inhibited the LC3A/B-II expression
levels which were fully rescued by mTOR knockdown or treatment of mTOR inhibitors in
vitro. The results illustrated that repression of autophagy by TF/FVII/PAR2 relies upon mTOR
activity.
Our study indicated that recombinant FVII, TF, and a PAR2 agonist increased expression of
mTOR whereas thrombin or PAR1 agonists did not. Gene silencing of FVII, TF, or PAR2
decreased mTOR. The decrease of LC3A/B-II initiated by recombinant FVII/TF/PAR2 agonist
was rescued by mTOR knockdown in vitro. These results indicated an mTOR-dependent
repression of autophagy by the FVII/TF/PAR2 signaling.
Although our observations suggest that the inhibition of autophagy by the FVII/TF/PAR2
signaling involves mTOR activity, targeting mTOR itself may result in differential outcomes.
The relationship between autophagy and mTOR signaling has been comprehensively studied
in terms of tumor suppression. However, administration of metformin, which negatively
regulates mTOR by activating adenosine monophosphate kinase (AMPK), shows a contradic-
tory effect, suggesting that blockade of mTOR activity does not always lead to autophagy [54].
Other signaling companions may be responsible. Another example is sirolimus (rapamycin).
Our results showed that an increase of LC3A/B-II by sirolimus was partially inhibited by
recombinant TF and completely blocked in the presence of recombinant FVII or a PAR2 agonist.
Taken together, our results highlight an essential role of the FVII/TF/PAR2 signaling in
regulation of autophagy in HCC, which nicely correlates with our observations in clinical and
animal research (Figure 1). In addition, a recent study demonstrated differential effects of
valproic acid-induced autophagy among various human prostate cancer cell lines. The
differences were likely due to the existence of alternatively spliced, inactive forms of Atg5 that
dampens the formation of Atg12-Atg5 conjugates [55]. Therefore, careful interpretation is
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necessary especially in cancer research when aberrant signaling in the autophagic pathway
may result from gene variants that do not normally exist in cells.
Figure 1. Schematic representation shows that PAR2 transduces the TF/FVII coagulation signaling through mTOR-de-
pendent inhibition in autophagy flux, which may facilitate development and progression of HCC.
Our recent study has demonstrated that the activation of the FVII/TF/PAR2 axis correlates with
increased migratory and invasive properties in HCC cells [56]. This finding can be consistently
recapitulated in tumor tissues of HCC patients, in which we found that increased levels of FVII
and PAR2 were significantly correlated with clinical staging, increased invasion and worse
disease-free survival. Notably, the signals that drive FVII/PAR2 stimulation toward cell
migration are mainly through ERK-TSC, independent of other coagulation effectors such as
thrombin/PAR1. Interestingly, in our cellular model, only FVII, but not soluble TF, activates
ERK1/2 through PAR2 signaling. Gene knockdown of FVII abrogates migration and invasion
of HCC cells more effectively than knocking down TF. Our speculation is that TF is constitu-
tively expressed in HCC tissue, and therefore, the cells are less sensitive to changes in TF levels.
Therefore, the amount of FVIIa determines the ratio that is engaged to regulate PAR2 signaling.
Although TF upregulation is well linked to aggressiveness in several cancers, our results are
more consistent with the findings from Rullier et al., in which no association between TF levels
and clinicopathological characteristics of HCC was found [57]. Several studies also show
limited contribution of TF to tumor growth [58–60]. Therefore, the role of TF in cancer
progression may be essential in some but not all cancers, and TF may not be a reliable
prognostic marker at least for HCC progression. In addition, the animal model using mouse
xenografts can well reflect our clinical findings in which we found that FVIIa administration
only positively affected vascular density but not size and number of the inoculated tumor.
These results were consistent with the expression of FVII in liver tissues of HCC patients which
was associated with vascular invasion and capsulations but not the number and size of tumor.
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It has been generally accepted that tumor cell motility is necessary for cancer metastasis [61].
The molecular basis to acquire ability to colonize other organs by invading tumor cells has
been long studied, but it remains an unmet challenge in therapeutic control on disseminated
tumors [62, 63]. Especially in China and other East Asian countries, survival of HCC patients
has improved due to advanced surgical skills and technologies such as orthotopic liver
transplantation and perioperative medication, prognosis and long-term survival after surgical
resection remains low owing to risk of invasive recurrence [64, 65]. Thus, there is an urgent
need to identify new targets responsible for impaired metastatic mechanisms and develop of
novel therapeutic strategies as well as preoperative biomarkers that supplement current
treatment protocols. Although potential risk of bleeding using specific FVII antagonists exists,
a recent clinical study has claimed that PCI-27483, a selective inhibitor of FVIIa, is well tolerated
in advanced pancreatic cancer patients [44]. Our previous studies also found that two meta-
static suppressors, NME/NM23 nucleoside diphosphate kinase 1 (NME1) and the basic helix-
loop-helix family member e41 (BHLHE41), were highly induced in FVII/PAR2 knocked down
HCC cells. These findings support the idea of targeting the FVII/PAR2 pathway and provide
mechanistic insights that specific members involved in autophagic flux could be potential
targets for treatment of metastatic HCC.
Emerging cohort studies indicate that HCC is currently the major cause of death in patients
with compensated hepatic cirrhosis. The mortality rate of HCC associated with cirrhosis is
increasing, whereas mortality rate from non-HCC complications with cirrhosis is reducing and
stable. Viral-related cirrhosis especially with hepatitis C virus infection is associated with the
highest HCC incidence in cirrhotic cases, occurring with almost two times in East Asia than in
the West [66]. Liver cirrhosis is a slowly progressive disease that enhances extracellular matrix
(ECM) accumulation after chronic injury, in which healthy liver tissue is replaced with scar
tissue and poor function is seen at the terminal stages.
It is generally accepted that the vast majority of chronic liver disease patients with cirrhosis
have a dysregulated coagulation system [67, 68]. A growing number of studies represented a
thrombotic risk in patients with chronic liver disease [69–72]. Thus, the reevaluation of
homeostasis in patients with thrombotic tendency in cirrhosis challenges the dogma that
considered this coagulopathy an acquired bleeding disorder and featured in most hematology
textbooks [67]. However, the mechanistic basis for this hypercoagulable state in cirrhotic
patients of chronic liver disease is not yet understood. A recent study have suggested that
hepatocytes are the source of increased TF microparticles, and hepatocyte TF may contribute
to the activation of coagulation in patients with chronic liver disease [42]. We recently dem-
onstrated that hepatic steatosis and liver injury by alcohol (AFLD) were exacerbated by
chloroquine (an autophagy inhibitor), but alleviated by carbamazepine (an autophagy
promoter) or rapamycin (an mTOR inhibitor) [73]. The protective effects of carbamazepine and
rapamycin in reducing steatosis were also represented in high fat diet-induced non-alcoholic
fatty liver conditions (NAFLD). Furthermore, we also found that a second autophagy promoter
amiodarone significantly reduced liver injury and improved liver regeneration and survival
after 90% partial hepatectomy in a mouse model [74]. Our data suggests that pharmacological
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modulation of autophagy in the liver can be an effective strategy for alleviating liver injury,
improve proliferative recovery, and may also ameliorate progression of liver cirrhosis.
Taken together, TF/FVII signaling is the main initiator of the extrinsic coagulation cascade,
which is also the major contributor in modulating the systemic balance of homeostasis in
healthy persons as well as in response to the pathogenesis in patients with chronic liver disease.
Amiodarone is now a potential drug to treat HCC through the modulation of autophagy to
decrease oncogenic miR-224 expression [75]. Thus, increasing evidences including our studies
support a close relationship between TF/FVII coagulation and liver disease in association with
reduced autophagy, suggesting pharmacological modulation of autophagy for AFLD, NAFLD,
and/or HCC could be a potential strategy for clinical uses.
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